Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BENEFIT 11 long-term follow-up study in patients with a first demyelinating event suggestive of multiple sclerosis
NL-OMON38856Phase 4Withdrawn
- Sponsor
- Bayer
- Start
- Jul 2013
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of interferon beta-1a in multiple sclerosis (MS) and clinically isolated syndrome (CIS), sponsored by Bayer. Primary endpoints: Conversion to clinically-definite multiple sclerosis, Change in disability and 3 more. Planned start Jul 2013; status: withdrawn.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on NL-OMON38856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38856.